Want to see IFF full AI Analyst Report?
Revenue by Segment
Highlights revenue contributions from different business segments, indicating which areas drive growth and profitability, and where strategic shifts might be needed.
The series shows a clear portfolio reshaping: Nourish/Food Ingredients and parts of Pharma Solutions drop out as divestitures/reclassifications, while Taste and Health & Biosciences re-emerge and steadily grow—consistent with management’s stated sale of commodity soy/crush assets and a Food Ingredients sale process. That mix shift helps explain Q1 margin expansion (higher‑margin, volume‑led H&B and Taste) even as Scent faces commodity pressure; investors should watch near‑term Q2 phasing and cash‑proceeds timing as pricing surcharges and passthroughs roll in.
IFF Revenue by Segment
| Date | Taste | Nourish | Health and Biosciences | Scent | Pharma Solutions |
|---|---|---|---|---|---|
| Jun 30, 2026 | $688.00M | $0.00 | $601.00M | $665.00M | $0.00 |
| Mar 31, 2026 | $656.00M | $0.00 | $595.00M | $651.00M | $0.00 |
| Dec 31, 2025 | $588.00M | $0.00 | $589.00M | $610.00M | $0.00 |
| Sep 30, 2025 | $635.00M | $0.00 | $577.00M | $652.00M | $0.00 |
| Jun 30, 2025 | $631.00M | $0.00 | $577.00M | $603.00M | $103.00M |
| Mar 31, 2025 | $627.00M | $0.00 | $540.00M | $614.00M | $266.00M |
| Dec 31, 2024 | $0.00 | $1.41B | $553.00M | $579.00M | $228.00M |
| Sep 30, 2024 | $0.00 | $1.49B | $570.00M | $613.00M | $256.00M |
| Jun 30, 2024 | $0.00 | $1.48B | $558.00M | $603.00M | $250.00M |
| Mar 31, 2024 | $0.00 | $1.50B | $531.00M | $645.00M | $227.00M |
| Dec 31, 2023 | $0.00 | $1.39B | $528.00M | $578.00M | $203.00M |
| Sep 30, 2023 | $0.00 | $1.45B | $518.00M | $615.00M | $238.00M |
| Jun 30, 2023 | $0.00 | $1.56B | $522.00M | $592.00M | $251.00M |
| Mar 31, 2023 | $0.00 | $1.65B | $513.00M | $608.00M | $253.00M |
| Dec 31, 2022 | $0.00 | $1.58B | $501.00M | $545.00M | $221.00M |
| Sep 30, 2022 | $0.00 | $1.70B | $512.00M | $591.00M | $257.00M |
| Jun 30, 2022 | $0.00 | $1.82B | $665.00M | $580.00M | $244.00M |
| Mar 31, 2022 | $0.00 | $1.73B | $661.00M | $585.00M | $249.00M |
| Dec 31, 2021 | $0.00 | $1.63B | $646.00M | $555.00M | $204.00M |
| Sep 30, 2021 | $0.00 | $1.66B | $618.00M | $580.00M | $211.00M |
| Jun 30, 2021 | $0.00 | $1.67B | $639.00M | $550.00M | $232.00M |
| Mar 31, 2021 | $0.00 | $1.31B | $426.00M | $569.00M | $162.00M |
| Dec 31, 2020 | $765.90M | $0.00 | $0.00 | $504.18M | $0.00 |
| Sep 30, 2020 | $765.24M | $0.00 | $0.00 | $502.84M | $0.00 |
| Jun 30, 2020 | $748.32M | $0.00 | $0.00 | $450.45M | $0.00 |
| Mar 31, 2020 | $830.32M | $0.00 | $0.00 | $517.00M | $0.00 |
